Locations:
SearchAdvertisement
Real-world results reporting aims to make treatments safer and more effective
Blinatumomab plus chemotherapy improves overall survival and relapse-free survival over chemotherapy alone
Patients receive specialized inpatient and outpatient care for cellular, gene and immune cell-engaging therapies
Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Clinicians highlight the need to educate patients about warning signs
Combination therapy demonstrates effectiveness in first-line treatment setting
Research indicates strong rationale for expanding trial eligibility criteria
Dedicated investigators and clinicians bring expertise in drug development and flexible study design
Timing of adjuvant immunotherapy unclear for maximum overall survival
Forecasting tool outperforms individual biomarkers
Advertisement
Advertisement